×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Company: Parkinson's Disease Synaptic Dysfunction Therapeutic Compani
company
1,489 words
Contents
Parkinson's Disease Synaptic Dysfunction Therapeutic Companies
No AI portrait yet
Generate portrait ✦
Agent Input
💡 Improve this page
🌐 Cross-references
Crunchbase
Wikipedia
Related Hypotheses (11)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.38
APOE-Dependent Autophagy Restoration
Score: 0.89
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.82
Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.72
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.65
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.62
TFEB-PGC1α Mitochondrial-Lysosomal Decoupling
Score: 0.62
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m
Score: 0.62
Synaptic Vesicle Tau Capture Inhibition
Score: 0.58
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.54
Related Analyses (23)
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Synaptic pruning by microglia in early AD
neurodegeneration · completed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Show 18 more
Related Experiments (30)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · completed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
validation · proposed · Score: 0.40
AAV-LRRK2 Gene Therapy IND-Enabling Study Design
clinical · proposed · Score: 0.40
LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne
validation · completed · Score: 0.40
Show 25 more
Knowledge Graph (8 edges)
microbiota-gut-brain axis
associated_with
Parkinson's disease
MBP
upregulates
Parkinson's Disease Dementia
PLP1
upregulates
Parkinson's Disease Dementia
Microbiota-Gut-Brain Axis
mediates
Parkinson's Disease Progression
Gut Microbiota Composition
correlates_with
Parkinson's Disease Development
Single-Nucleus RNA Sequencing
associated_with
Parkinson's Disease Molecular Drivers
Viral Infections
risk_factor_for
Parkinson's Disease Progression
Parkinson's Disease Dementia
associated_with
Dementia with Lewy Bodies
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.